OncoMatch/Clinical Trials/NCT06039371
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
Is NCT06039371 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Carboplatin and Etoposide for castration-resistant prostate carcinoma.
Treatment: Carboplatin · Etoposide · Testosterone Cypionate — This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment, and Lutetium 177Lu-prostate specific-membrane antigen (PSMA)-617 (LuPSMA) in patients with prostate cancer that has progressed despite being previously treated with androgen therapies and has spread from where it first started (prostate) to other places in the body (metastatic castration-resistant prostate cancer). In patients that have developed progressive cancer in spite of standard hormonal treatment, administering supraphysiological testosterone may result in regression of tumors by causing deoxyribonucleic acid (DNA) damage in tumor cells that have adapted to low testosterone conditions. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Radioactive drugs, such as LuPSMA, may carry radiation directly to tumor cells and not harm normal cells. Giving supraphysiological levels of testosterone and carboplatin or etoposide or LuPSMA together may be an effective treatment for metastatic castration-resistant prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage IVB (AJCC v8)
Metastatic disease required
Stage IVB Prostate Cancer AJCC v8
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: androgen receptor-signalling inhibitor (abiraterone, enzalutamide) — metastatic castration-resistant prostate cancer
Patients must have progressed on at least one prior next-generation androgen receptor-signalling inhibitor (e.g., abiraterone, enzalutamide, etc.)
Cannot have received: chemotherapy
Exception: Patients may have received docetaxel for the treatment of hormone-sensitive prostate cancer
No prior chemotherapy for the treatment of mCRPC. Patients may have received docetaxel for the treatment of hormone-sensitive prostate cancer
Lab requirements
Blood counts
Hemoglobin >= 9 g/dL with no blood transfusion in the past 28 days; ANC >= 1.5 x 10^9/L; Platelet count >= 100 x 10^9/L
Kidney function
creatinine clearance >= 51 mL/min (Cockcroft-Gault or 24 hour urine test)
Liver function
Total bilirubin <= 1.5 x institutional upper limit of normal (ULN); AST/ALT <= 2.5 x ULN unless liver metastases are present in which case they must be <= 5x ULN
Hemoglobin >= 9 g/dL with no blood transfusion in the past 28 days (within 30 days prior to administration of study treatment); Absolute neutrophil count (ANC) >= 1.5 x 10^9/L; Platelet count >= 100 x 10^9/L; Total bilirubin <= 1.5 x institutional upper limit of normal (ULN); AST/ALT <= 2.5 x ULN unless liver metastases are present in which case they must be <= 5x ULN; creatinine clearance >= 51 mL/min (Cockcroft-Gault or 24 hour urine test)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify